Cargando…

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota

INTRODUCTION: This study was designed to identify a group of bacteria in the human gut microbiota with specific effects on PD-1-based immunotherapy for patients with non-small cell lung cancer (NSCLC). METHODS: The study was performed in patients with advanced NSCLC, who received PD-1 monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Daqiang, Li, Xing, An, Rui, Wang, Lihong, Wang, Yun, Zheng, Song, Chen, Xueqing, Wang, Xianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593091/ https://www.ncbi.nlm.nih.gov/pubmed/34664203 http://dx.doi.org/10.1007/s40487-021-00171-3

Ejemplares similares

Intermittent Parathyroid Hormone Alters Gut Microbiota in Ovariectomized Osteoporotic Rats
por: Zhou, Jiaming, et al.
Publicado: (2022)

PD-1 deficiency protects experimental colitis via alteration of gut microbiota
por: Park, Seong Jeong, et al.
Publicado: (2017)

Gut Microbiota and Immunotherapy
por: Xu, Xiaoqing, et al.
Publicado: (2022)

Alteration of the Gut Microbiota in Missed Abortion
por: Chen, Yi, et al.
Publicado: (2023)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota
por: Wei, Yibing, et al.
Publicado: (2023)

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
por: Zheng, Yi, et al.
Publicado: (2019)

The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B
por: Wang, Lixue, et al.
Publicado: (2023)

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
por: Liu, Xiangjun, et al.
Publicado: (2021)

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
por: Lu, Yuting, et al.
Publicado: (2022)

Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
por: An, Rui, et al.
Publicado: (2021)

Alterations of gut microbiota contribute to the progression of unruptured intracranial aneurysms
por: Li, Hao, et al.
Publicado: (2020)

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
por: Carbone, Carmine, et al.
Publicado: (2019)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Emerging roles of the gut microbiota in cancer immunotherapy
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Alterations of gut microbiota in a mouse model with partial small intestinal obstruction
por: Wang, Yong, et al.
Publicado: (2023)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy
por: Wang, Meiqi, et al.
Publicado: (2023)

Gut Microbiota and the Paradox of Cancer Immunotherapy
por: Poutahidis, Theofilos, et al.
Publicado: (2014)

The Role of Gut Microbiota in Tumor Immunotherapy
por: Wu, Miao, et al.
Publicado: (2021)

Gut Microbiota and Immunotherapy for Alzheimer’s Disease
por: Dai, Chun-Ling, et al.
Publicado: (2022)

Alterations of the Gut Microbiota in Multiple System Atrophy Patients
por: Wan, Linlin, et al.
Publicado: (2019)

Alterations of lung microbiota in patients with non-small cell lung cancer
por: Zeng, Wen, et al.
Publicado: (2022)

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
por: Huang, Jumin, et al.
Publicado: (2022)

Alterations in the gut microbiota of AIDS patients with pneumocystis pneumonia and correlations with the lung microbiota
por: Zhu, Mingli, et al.
Publicado: (2022)

Effects of the Lipid Metabolites and the Gut Microbiota in ApoE(−/−) Mice on Atherosclerosis Co-Depression From the Microbiota-Gut-Brain Axis
por: Hu, Ke, et al.
Publicado: (2022)

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
por: Yan, Jipeng, et al.
Publicado: (2022)

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
por: Wang, Limin, et al.
Publicado: (2023)

Alteration and clinical potential in gut microbiota in patients with cerebral small vessel disease
por: Shi, Yachen, et al.
Publicado: (2023)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

Corrigendum: Alterations of the Gut Microbiota in Multiple System Atrophy Patients
por: Wan, Linlin, et al.
Publicado: (2020)

Altered gut microbiota in temporal lobe epilepsy with anxiety disorders
por: Wei, Shouchao, et al.
Publicado: (2023)

Small Bowel Transit and Altered Gut Microbiota in Patients With Liver Cirrhosis
por: Liu, Yang, et al.
Publicado: (2018)

Structural and quantitative alterations of gut microbiota in experimental small bowel obstruction
por: Mo, Jiali, et al.
Publicado: (2021)

Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients
por: Zhao, Feng, et al.
Publicado: (2021)

Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
por: Hou, Xinxin, et al.
Publicado: (2022)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021)

Gut microbiota: impacts on gastrointestinal cancer immunotherapy
por: Lau, Harry Cheuk Hay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nhorvlia7mrvolpq6mll39die7